Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ELANE | P08246 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5317587 | 0.85 | KMT2A (0.69) | KMT2ACYP2C19CNR1ALDH1A1MEN1 | |
| SCHEMBL13879509 | 0.80 | KMT2A (0.91) | KMT2ACYP2C19ALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL3249503 | 0.77 | KMT2A (0.75) | KMT2ACYP2C19CNR1ALDH1A1ELANE | |
| SCHEMBL25000449 | 0.76 | KMT2A (0.53) | KMT2ACYP2C19CNR1ALDH1A1ELANE | |
| SCHEMBL3233520 | 0.76 | KMT2A (0.73) | KMT2ACYP2C19CNR1ALDH1A1ELANE | |
| Hydrochloric Acid SCHEMBL23610493 | 0.76 | KMT2A (0.73) | KMT2ACYP2C19CNR1ALDH1A1ELANE | |
| SCHEMBL30180963 | 0.75 | KMT2A (0.56) | KMT2ACYP2C19CNR1ALDH1A1ELANE | |
| SCHEMBL2907609 | 0.75 | KMT2A (0.62) | KMT2ACYP2C19CNR1ALDH1A1ELANE | |
| SCHEMBL9965983 | 0.75 | KMT2A (0.71) | KMT2ACYP2C19CNR1ALDH1A1ELANE | |
| SCHEMBL11492041 | 0.74 | KMT2A (0.61) | KMT2ACYP2C19CNR1ALDH1A1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | KMT2A 499/4885CYP2C19 3692/4885CNR1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.